Franklin Biotechnology Discovery Fund Advisor Class (FTDZX)

NASDAQ · Mutual Fund · Delayed Price · Currency is USD
126.79
+3.89 (3.17%)
Jul 9, 2025, 9:30 AM EDT
-14.23%
Fund Assets 676.00M
Expense Ratio 0.80%
Min. Investment $1,000
Turnover 35.87%
Dividend (ttm) 11.76
Dividend Yield 9.28%
Dividend Growth n/a
Payout Frequency n/a
Ex-Dividend Date Dec 20, 2024
Previous Close 122.90
YTD Return -0.10%
1-Year Return -4.51%
5-Year Return -8.51%
52-Week Low 104.73
52-Week High 160.08
Beta (5Y) n/a
Holdings 88
Inception Date Sep 1, 2009

About FTDZX

Franklin Biotechnology Discovery Fund Advisor Class is a mutual fund that focuses on delivering capital appreciation by investing primarily in the biotechnology sector. Under normal market conditions, the fund allocates at least 80% of its net assets to equity securities of biotechnology companies and discovery research firms—enterprises that derive a significant portion of their revenue from biotechnology-related activities. The fund’s portfolio often includes both established and emerging biotechnology firms, with a notable allocation to smaller capitalization companies, typically those with market values below $2 billion at the time of investment. While the fund maintains a majority exposure to U.S.-based companies, it may allocate up to 20% of its assets to foreign securities, including American, European, and Global Depositary Receipts. Managed using a fundamental, research-driven investment approach, the fund seeks out companies with identifiable drivers of future earnings growth and sustainable growth characteristics. Franklin Biotechnology Discovery Fund Advisor Class plays a significant role in offering investors a specialized vehicle for gaining exposure to innovations and growth opportunities within the global biotechnology industry, reflecting both the sector’s risk profile and potential for long-term growth.

Fund Family Franklin Templeton Investments
Category Health
Stock Exchange NASDAQ
Ticker Symbol FTDZX
Share Class Advisor Class
Index NASDAQ Biotechnology CR

Performance

FTDZX had a total return of -4.51% in the past year, including dividends. Since the fund's inception, the average annual return has been 10.07%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol Share Class Expense Ratio
FRBRX Class R6 0.69%
FBDIX Class A 1.05%
FBTDX Class C 1.80%

Top 10 Holdings

49.47% of assets
Name Symbol Weight
Gilead Sciences, Inc. GILD 8.17%
Amgen Inc. AMGN 7.64%
Vertex Pharmaceuticals Incorporated VRTX 7.25%
Ascendis Pharma A/S ASND 4.89%
Regeneron Pharmaceuticals, Inc. REGN 4.34%
argenx SE ARGX 3.80%
Jazz Pharmaceuticals plc JAZZ 3.79%
Merus N.V. MRUS 3.52%
PTC Therapeutics, Inc. PTCT 3.16%
Neurocrine Biosciences, Inc. NBIX 2.91%
View More Holdings

Dividend History

Ex-Dividend Amount Pay Date
Dec 20, 2024 $11.7607 Dec 20, 2024
Dec 20, 2022 $0.4163 Dec 20, 2022
Dec 15, 2021 $18.0843 Dec 15, 2021
Dec 15, 2020 $10.3921 Dec 15, 2020
Dec 16, 2019 $14.1643 Dec 18, 2019
Dec 17, 2018 $4.5496 Dec 19, 2018
Full Dividend History